Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,661 public trials 322 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

NCT00036140

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Research Center Los Angeles, California, United States
  • Research Center Los Angeles, California, United States
  • Research Center Rancho Mirage, California, United States
  • Research Center Cleveland, Ohio, United States
View Trial Details
Active, Not Recruiting

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

NCT07030517

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • M S Ramaiah Medical College and Hospital Bangalore, India
  • St. Johns Medical College And Hospital Bengaluru, India
  • Post Graduate Institute of Medical Education And Research PGIMER Chandigarh, India
  • Bhagwan Mahaveer Cancer Hospital & Research Centre Jaipur, India
View Trial Details
Active, Not Recruiting

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute Emory University Atlanta, Georgia, United States
View all 27 locations
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1411 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab

NCT05438043

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Miami Sylvester Cancer Center Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Barnes-jewish Hospital St Louis, Missouri, United States
View all 92 locations
View Trial Details
Active, Not Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Augusta University- Georgia Cancer Center Augusta, Georgia, United States
View all 53 locations
View Trial Details
Active, Not Recruiting

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

NCT06323447

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B Cell Lymphoma, +18 more
Locations
  • University of Hawaii Cancer Center Honolulu, Hawaii, United States
  • Norton Healthcare Cancer Center Louisville, Kentucky, United States
  • Massachussetts General Hospital Boston, Massachusetts, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Active, Not Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF Fresno Clovis, California, United States
  • UCLA Santa Monica, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Medical Oncology Hematology Consultants, PA Newark, Delaware, United States
View all 242 locations
View Trial Details
Active, Not Recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

NCT04140162

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Michigan Rogel Cancer Center Ann Arbor, Michigan, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • University of Rochester Rochester, New York, United States
  • University of Texas Southwestern -- Simmons Comprehensive Cancer Center Dallas, Texas, United States
View Trial Details

Related conditions